search
Back to results

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

Primary Purpose

Insomnia Disorder

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Zolpidem
Sponsored by
Idorsia Pharmaceuticals Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Insomnia Disorder focused on measuring insomnia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent prior to any study-mandated procedure;
  • Male or female aged ≥ 18 years;
  • Body mass index (BMI): 18.5 ≤ BMI (kg/m2) < 32.0;
  • Insomnia disorder according to DSM-5 criteria;
  • Insufficient sleep quantity evaluated according to the self-reported history and data collected in the sleep diary;
  • Insomnia Severity Index score greater than or equal to 15;
  • Complete the IDSIQ™ and the sleep diary questionnaire as required.

Exclusion Criteria:

  • Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement behavior disorder, or narcolepsy;
  • Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week;
  • Caffeine consumption ≥ 600 mg per day;
  • Shift work within 2 weeks prior to the screening visit, or planned shift work from V1 to V3;
  • Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel ≥ 3 time zones from V1 to V3;
  • Known severe renal impairment or know moderate or severe hepatic impairment;
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Sites / Locations

  • Santa Monica Clinical Trials
  • Neurotrials Research Inc
  • Clinical Research CTR of Nevada
  • Clinilabs NYC
  • CTI Clinical Research Center
  • St-Hedwig Krankenhaus, Schlaflab
  • Advanced Sleep Research Berlin
  • CTC North, Universitätsklinikum Hamburg- Eppendorf
  • Somnibene Inst Med Forschung & Schlafmedizin

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Zolpidem

Arm Description

Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study

Outcomes

Primary Outcome Measures

Content validity of the IDSIQ™: scoring of items into domains
Content validity will be based on the combination of qualitative and statistical methods in order to generate a scoring algorithm

Secondary Outcome Measures

Psychometric validitiy of the IDSIQ™: Internal reliability
Internal consistency reliability assesses the extent to which the items correlate which each other within their domain and it is evaluated by correlation scores
Psychometric validitiy of the IDSIQ™: Test-retest reliability
Test-retest reliability assesses the reproducibility of the domain scores during a specific time period of stable condition and it is evaluated by intraclass correlation coefficients
Psychometric validitiy of the IDSIQ™: sensitivity to change
Changes in the IDSIQ domain scores after 2 weeks of treatment with zolpidem compared to baseline (before zolpidem administration)

Full Information

First Posted
January 31, 2017
Last Updated
July 23, 2019
Sponsor
Idorsia Pharmaceuticals Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03056053
Brief Title
Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder
Official Title
Multi-center, Single-arm, Open-label Study in Patients With Insomnia Disorder to Validate the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
February 15, 2017 (Actual)
Primary Completion Date
April 21, 2017 (Actual)
Study Completion Date
May 5, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Idorsia Pharmaceuticals Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main study objective is to assess the content validity and the psychometric characteristics of the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™).
Detailed Description
Zolpidem will be used as an active intervention to assess the sensitivity to change of IDSIQ™ in patients suffering from insomnia disorder. IDSIQ™ will be administered during the screening period (within 14 days before enrollment in the study) and the treatment period (from Day 1 to Day 14). End of study (phone call) will take place 30-37 days after the end-of-treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia Disorder
Keywords
insomnia

7. Study Design

Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
113 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Zolpidem
Arm Type
Other
Arm Description
Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
Intervention Type
Drug
Intervention Name(s)
Zolpidem
Other Intervention Name(s)
Ambien, Zolpidem generics, Stilnox
Intervention Description
Commercially available tablets of zolpidem (5 or 10 mg) for oral use
Primary Outcome Measure Information:
Title
Content validity of the IDSIQ™: scoring of items into domains
Description
Content validity will be based on the combination of qualitative and statistical methods in order to generate a scoring algorithm
Time Frame
During the screening period, i.e. within 14 days before Day 1
Secondary Outcome Measure Information:
Title
Psychometric validitiy of the IDSIQ™: Internal reliability
Description
Internal consistency reliability assesses the extent to which the items correlate which each other within their domain and it is evaluated by correlation scores
Time Frame
During the screening period, i.e. within 14 days before Day 1
Title
Psychometric validitiy of the IDSIQ™: Test-retest reliability
Description
Test-retest reliability assesses the reproducibility of the domain scores during a specific time period of stable condition and it is evaluated by intraclass correlation coefficients
Time Frame
During the screening period, i.e. within 14 days before Day 1
Title
Psychometric validitiy of the IDSIQ™: sensitivity to change
Description
Changes in the IDSIQ domain scores after 2 weeks of treatment with zolpidem compared to baseline (before zolpidem administration)
Time Frame
At Week 1 and Week 2

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent prior to any study-mandated procedure; Male or female aged ≥ 18 years; Body mass index (BMI): 18.5 ≤ BMI (kg/m2) < 32.0; Insomnia disorder according to DSM-5 criteria; Insufficient sleep quantity evaluated according to the self-reported history and data collected in the sleep diary; Insomnia Severity Index score greater than or equal to 15; Complete the IDSIQ™ and the sleep diary questionnaire as required. Exclusion Criteria: Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement behavior disorder, or narcolepsy; Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week; Caffeine consumption ≥ 600 mg per day; Shift work within 2 weeks prior to the screening visit, or planned shift work from V1 to V3; Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel ≥ 3 time zones from V1 to V3; Known severe renal impairment or know moderate or severe hepatic impairment; History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments; Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Mangialaio, MD
Organizational Affiliation
Actelion
Official's Role
Study Director
Facility Information:
Facility Name
Santa Monica Clinical Trials
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Neurotrials Research Inc
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Clinical Research CTR of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89104
Country
United States
Facility Name
Clinilabs NYC
City
New York
State/Province
New York
ZIP/Postal Code
10019
Country
United States
Facility Name
CTI Clinical Research Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45255
Country
United States
Facility Name
St-Hedwig Krankenhaus, Schlaflab
City
Berlin
ZIP/Postal Code
10115
Country
Germany
Facility Name
Advanced Sleep Research Berlin
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
CTC North, Universitätsklinikum Hamburg- Eppendorf
City
Hamburg
ZIP/Postal Code
20251
Country
Germany
Facility Name
Somnibene Inst Med Forschung & Schlafmedizin
City
Schwerin
ZIP/Postal Code
19053
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
33131027
Citation
Hudgens S, Phillips-Beyer A, Newton L, Seboek Kinter D, Benes H. Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Patient. 2021 Mar;14(2):249-268. doi: 10.1007/s40271-020-00474-z. Epub 2020 Nov 1.
Results Reference
derived

Learn more about this trial

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

We'll reach out to this number within 24 hrs